Introduction {#sec1-1}
============

Her-2 neu (or Cerb B-2) protooncogene is amplified in nearly 10%--30% of breast carcinomas and is an indicator of clinical tumor aggressiveness and poor prognosis.\[[@ref1]\] Her-2 neu has become an essential part of the clinical evaluation of breast cancer patients to select those patients suitable for a treatment regimen with a humanized monoclonal antibody trastuzumab (Herceptin; Genentech, San Francisco, CA, USA).\[[@ref2]\] Fluorescent *in-situ* hybridization (FISH) and immunohistochemistry (IHC) are two major detection methods in routine clinical practice. In most centres, IHC is used as a screening technique for assessing Her-2 neu status and then FISH is used for those cases that are weakly positive or show indeterminate staining pattern.\[[@ref1]\] Her-2 neu expression has been extensively studied on surgically excised breast tissue sections but few studies demonstrate it by FISH technique on cytological specimens namely imprints and aspirate smears.\[[@ref3]\] Occasional studies have applied chromogenic *in-situ* hybridization (CISH) technique on cytologic samples\[[@ref4]\] and found monolayer preparations to give excellent results. Evaluation of Her-2 neu status in cytology samples has a lot of clinical relevance as the sample can be obtained prior to surgery and help plan management of patients with inoperable breast carcinoma. This pilot study was undertaken to evaluate Her-2 neu on cytospin smears from fine needle aspirates (FNA) of breast carcinoma patients and determine if IHC, FISH or CISH is better suited.

Materials and Methods {#sec1-2}
=====================

Twenty samples of FNA collected for diagnostic purposes from histologically documented primary ductal breast carcinoma were studied. In 18 patients Her-2 neu expression had also been determined on tissue sections for patient care.

Cytospin smears prepared from FNA were fixed in 95% ethanol. The prefixed unstained cytospin smear was used to demonstrate Her-2 neu by IHC, FISH and CISH using standard protocols.\[[@ref5]\] The source of the antibody for IHC was DAKO (Cat No. A0485), dilution of antibody (1:50) and detection system LSAB2^®^ System-HRP, DAKO (Cat No. K 0675); FISH VYSIS PathvisionR HER-2 DNA Probe kit and CISH. CISH -- ZYMED SPoT-Light^®^ HER-2 CISH TM Kit (Cat 84-0146)

Scoring System for Her-2 neu by IHC {#sec2-1}
-----------------------------------

0 -- No immunostaining

1+ -- Weak immunostaining, less than 30% of tumor cells

2+ -- Complete membranous staining, either uniform or weak in at least 10% of cells

3+ -- Uniform intense membranous staining in at least 30% of cells \[[Figure 1](#F1){ref-type="fig"}\].

![Her-2 neu expression by immunocytochemical studies on fine needle aspriates from breast carcinoma. a, b (Score 3); c (Score 1); d (Negative). (a,b,c,d ×400)](JCytol-28-54-g001){#F1}

Enumeration of Her-2 neu Amplification by FISH {#sec2-2}
----------------------------------------------

The total number of Her-2 neu and CEP 17 signals in 20-60 interphase tumor cells were counted. The Her-2/CEP 17 ratio was calculated by dividing the total counts of the Her-2 neu signals by the total counts of CEP 17 signals. The ratio of \>2.0 was defined as Her-2 neu DNA amplification. Ratio at or near the cut-off (1.8-\<2.0) was considered as borderline amplification \[[Figure 2](#F2){ref-type="fig"}\]. Ratios below 1.8 were considered as not amplified.

![Fluorescence *in-situ* hybridization (FISH) on fine needle aspriates from breast carcinoma. a, b (Case 1); c, d (Case 5): Cases 1 and 5 show amplified Her-2 neu (red) and normal CEP-17 (green). c, f (Case 12) Normal Her-2 neu (red) and CEP-17 (green). (a, c, e ×400; b, d, f ×1000)](JCytol-28-54-g002){#F2}

Evaluation of CISH Results {#sec2-3}
--------------------------

Amplification was considered to be high when more than 10 copies, or large clusters of the Her-2 neu gene were present in \>50% of cancer cell nuclei, whereas 6-10 copies of the Her-2 neu gene or a small Her-2 neu gene cluster, in the same percentage of cells were considered to be of low amplification \[[Figure 3](#F3){ref-type="fig"}\]. Tumors were not considered to be amplified when 1-5 copies of the Her-2 neu gene were identified per nucleus.

![CISH detection of Her-2 neu on fine needle aspirates from breast carcinoma. a,b (Case 3) low amplification (5 or more Her-2 neu gene signals); c,d (Case 5) High Amplification (brown clusters seen in the nuclei); e (Case 12): No amplification of Her-2 neu (2-3 Her-2 neu gene signals in each nucleus). (a, c, e ×400; b, d ×1000)](JCytol-28-54-g003){#F3}

Results {#sec1-3}
=======

In 12 of the 20 cytospin smears examined Her-2 neu detection was available by all the three methods. In 10 of these corresponding Her-2 neu results were available by IHC and FISH in tissue sections.

[Table 1](#T1){ref-type="table"} correlates the expression of Her-2 neu by IHC, FISH and CISH in cytospin smears and tissue sections. Of the 7 cases negative/1+ for Her-2 neu by IHC -- 3 and 5 were also negative by FISH and CISH, respectively. Three of the 5 cases with 2+ and 3+ staining by IHC also showed gene amplification by FISH and CISH.

###### 

Correlation of expression of Her-2 neu by IHC, FISH and CISH in cytospin smears from fine needle aspirates of breast carcinoma

![](JCytol-28-54-g004)

Discussion {#sec1-4}
==========

The accuracy of diagnostic assays for Her-2 neu in breast cancer is extremely important as its over expression is clinically useful for predicting prognosis and identifying patients who may benefit from herceptin treatment. FNA is an established reliable method for the diagnosis of breast carcinoma. Its application has been extended to immunocytochemical analysis of prognostic indicators.\[[@ref6]\] Limited studies are available which document Her-2 neu status of breast carcinoma in FNA and most of the studies have used conventional smears.\[[@ref3]\] We have tried to document the reliability of Her-2 neu expression on cytospin smears from FNA by IHC, FISH and CISH to see which is better suited. Unfortunately, we were unable to demonstrate any consistency. Others have also shown that Her-2 neu protein expression on cytologic preparations by IHC is insufficiently reliable while gene amplification determined by FISH on FNA has been found to have consistent correlation with tissue sample.\[[@ref7]\] Within the FNA specimens, the agreement between protein overexpression (IHC) and gene amplification (FISH and CISH) was variable.\[[@ref3][@ref4][@ref7]\] This could be attributed to the method of fixation. It has been recently reported that poorest agreement was observed with immunocytochemical analysis performed on slides fixed in ethanol whereas there was little difference between formalin fixation and Thin-Prep slides.\[[@ref5]\] To conclude, it is possible to study Her-2 neu by IHC, FISH and CISH in cytologic material. However, it is not very reliable. Further studies are needed to standardize fixation techniques. Determining Her-2 neu status on aspirates may still be useful in patients with advanced cancer where surgical resection of the tumor may pose a problem and documenting Her-2 neu status is imperative prior to starting therapy.
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